
HIV Support Group
HIV (also known as human immunodeficiency virus, and formerly known as HTLV-III and lymphadenopathy-associated virus) is a retrovirus that primarily infects vital components of the human immune system which can lead the syndrome known as AIDS. Many of the problems faced by people infected with HIV result from failure of the immune system to protect from opportunistic...

deleted_user
Since the mid-1980's, low dose naltrexone (LDN) has consistently demonstrated a markedly beneficial effect in the treatment of HIV/AIDS.
This hit me as something to research....I have found a couple people here on DS that take it....anyone have more info???
http://lowdosenaltrexone.org/ldn_and_hiv.htm
Low-dose naltrexone holds great promise for the millions of people worldwide with
autoimmune diseases or central nervous system disorders or who face a deadly cancer.
LDN provides the first low-cost, easy to administer, and side-effect-free
therapy for HIV/AIDS.
In 1985, Bernard Bihari, MD, a physician with a clinical practice in New York City,
discovered the effects of a much smaller dose of naltrexone (approximately 3mg once a day)
on the body's immune system. He found that this low dose, taken at bedtime, was able to
enhance a patient's response to infection by HIV, the virus that causes AIDS.
[Note: Subsequently, the optimal adult dosage of LDN has been found to be 4.5mg.]
The brief blockade of opioid receptors between 2 a.m. and 4 a.m. that is caused by taking
LDN at bedtime each night is believed to produce a prolonged up-regulation of vital
elements of the immune system by causing an increase in endorphin and enkephalin
production. Normal volunteers who have taken LDN in this fashion have been found
to have much higher levels of beta-endorphins circulating in their blood in the following days.
Bihari says that his patients with HIV/AIDS who regularly took
LDN before the availability of HAART were generally spared any
deterioration of their important helper T cells (CD4+).
In general, in people with diseases that are partially or largely triggered by a deficiency
of endorphins (including cancer and autoimmune diseases), or are accelerated by a
deficiency of endorphins (such as HIV/AIDS), restoration of the body's normal production
of endorphins is the major therapeutic action of LDN.
HIV/AIDS. As of September 2003, Dr. Bihari had been treating 350 AIDS
patients using LDN in conjunction with accepted AIDS therapies. Over the prior
7 years over 85% of these patients showed no detectable levels of the HIV virus
a much higher success rate than most current AIDS treatments, and with no
significant side effects. It is also worth noting that many HIV/AIDS patients have
been living symptom-free for years taking only LDN with no other medications.
The usual adult dosage is 4.5mg taken once daily at night. Because of the rhythms of the
body's production of master hormones, LDN is best taken between 9pm and 3am.
Most patients take it at bedtime. People who have multiple sclerosis that has led to
muscle spasms are advised to use only 3mg daily and to maintain that dosage.
Rarely, the naltrexone may need to be purchased as a solution
in distilled water with 1mg per ml dispensed with a 5ml medicine dropper.
If LDN is used in a liquid form, it is important to keep it refrigerated.
The therapeutic dosage range for LDN is from 1.75mg to 4.5mg every night.
Dosages below this range are likely to have no effect at all, and dosages
above this range are likely to block endorphins for too long a period of time
and interfere with its effectiveness.
HIV/AIDS.
As an AIDS drug, LDN leads to far fewer side effects than the standard
"AIDS cocktail." When used in conjunction with HAART therapies, LDN can boost
T-cell populations, prevent disfiguring lipodystrophy, and lower rates of treatment failure.
Additional Information
Bernard Bihari, MD, is the discoverer of the major clinical effects of low dose naltrexone.
A private practitioner in Manhattan, he retired in March 2007. Dr. Bihari is a
Board-certified specialist in Psychiatry and Neurology. Dr. Bihari's curriculum vitae.
David Gluck, MD, is the editor of this website, ldninfo.org. He is a Board-certified
specialist in both Internal Medicine and Preventive Medicine. Dr. Gluck has served as
medical director for JCPenney and MetLife, and is now semi-retired, living and working in New York City.
Ian S. Zagon, PhD, has spent over two decades in doing basic research concerning endorphins.
He is Professor of Neural and Behavioral Sciences, Pennsylvania State University, Dept.
of Neural and Behavioral Sciences, H-109, Hershey Medical Center, Hershey, PA 17033; office phone:
(717) 531-6409; email: isz1@psu.edu; website.
This hit me as something to research....I have found a couple people here on DS that take it....anyone have more info???
http://lowdosenaltrexone.org/ldn_and_hiv.htm
Low-dose naltrexone holds great promise for the millions of people worldwide with
autoimmune diseases or central nervous system disorders or who face a deadly cancer.
LDN provides the first low-cost, easy to administer, and side-effect-free
therapy for HIV/AIDS.
In 1985, Bernard Bihari, MD, a physician with a clinical practice in New York City,
discovered the effects of a much smaller dose of naltrexone (approximately 3mg once a day)
on the body's immune system. He found that this low dose, taken at bedtime, was able to
enhance a patient's response to infection by HIV, the virus that causes AIDS.
[Note: Subsequently, the optimal adult dosage of LDN has been found to be 4.5mg.]
The brief blockade of opioid receptors between 2 a.m. and 4 a.m. that is caused by taking
LDN at bedtime each night is believed to produce a prolonged up-regulation of vital
elements of the immune system by causing an increase in endorphin and enkephalin
production. Normal volunteers who have taken LDN in this fashion have been found
to have much higher levels of beta-endorphins circulating in their blood in the following days.
Bihari says that his patients with HIV/AIDS who regularly took
LDN before the availability of HAART were generally spared any
deterioration of their important helper T cells (CD4+).
In general, in people with diseases that are partially or largely triggered by a deficiency
of endorphins (including cancer and autoimmune diseases), or are accelerated by a
deficiency of endorphins (such as HIV/AIDS), restoration of the body's normal production
of endorphins is the major therapeutic action of LDN.
HIV/AIDS. As of September 2003, Dr. Bihari had been treating 350 AIDS
patients using LDN in conjunction with accepted AIDS therapies. Over the prior
7 years over 85% of these patients showed no detectable levels of the HIV virus
a much higher success rate than most current AIDS treatments, and with no
significant side effects. It is also worth noting that many HIV/AIDS patients have
been living symptom-free for years taking only LDN with no other medications.
The usual adult dosage is 4.5mg taken once daily at night. Because of the rhythms of the
body's production of master hormones, LDN is best taken between 9pm and 3am.
Most patients take it at bedtime. People who have multiple sclerosis that has led to
muscle spasms are advised to use only 3mg daily and to maintain that dosage.
Rarely, the naltrexone may need to be purchased as a solution
in distilled water with 1mg per ml dispensed with a 5ml medicine dropper.
If LDN is used in a liquid form, it is important to keep it refrigerated.
The therapeutic dosage range for LDN is from 1.75mg to 4.5mg every night.
Dosages below this range are likely to have no effect at all, and dosages
above this range are likely to block endorphins for too long a period of time
and interfere with its effectiveness.
HIV/AIDS.
As an AIDS drug, LDN leads to far fewer side effects than the standard
"AIDS cocktail." When used in conjunction with HAART therapies, LDN can boost
T-cell populations, prevent disfiguring lipodystrophy, and lower rates of treatment failure.
Additional Information
Bernard Bihari, MD, is the discoverer of the major clinical effects of low dose naltrexone.
A private practitioner in Manhattan, he retired in March 2007. Dr. Bihari is a
Board-certified specialist in Psychiatry and Neurology. Dr. Bihari's curriculum vitae.
David Gluck, MD, is the editor of this website, ldninfo.org. He is a Board-certified
specialist in both Internal Medicine and Preventive Medicine. Dr. Gluck has served as
medical director for JCPenney and MetLife, and is now semi-retired, living and working in New York City.
Ian S. Zagon, PhD, has spent over two decades in doing basic research concerning endorphins.
He is Professor of Neural and Behavioral Sciences, Pennsylvania State University, Dept.
of Neural and Behavioral Sciences, H-109, Hershey Medical Center, Hershey, PA 17033; office phone:
(717) 531-6409; email: isz1@psu.edu; website.
Posts You May Be Interested In
-
theatre and I are there already. I'm having a very berry tea with crackers, cheese and cherry tomatoes and she's having a joint with some beer and we're both on really comfy recliners on thick pile carpet. we need some help with the decor if anyone is around??
-
I'm trying to exercise daily. I was doing fairly well until I sprained my ankle 2 weeks ago but now I'm getting back on the horse. Today I walked over a mile with my arm weights that are about 22lbs total. I was out of shape and it was hard on my arms. I also did my 30 situps. I'm also going to drink a lot of water and try to eat healthy. I do tend to have a sweet tooth but I'm cutting...
I can say that my dreams have become much more lucid and vivid since starting LDN. I have had several dreams about my deceased brother while taking LDN and if nothing else, those dreams have made it worth my while.
I had extreme fatigue when I first started LDN but I was also battling a diverticulitis attack so it is hard to say where the fatigue came from. I can honestly say now, my fatigue is pretty much dissipated and I feel GREAT!
I have learned a lot about LDN from a Yahoo Group and if you are interested, here is the link to that group.
http://health.groups.yahoo.com/group/lowdosenaltrexone/
I must warn you, that group gets A LOT of email so you may want to set your mail to be delivered as a digest so you do not get overwhelmed.
Hope this helps.
BE WELL.